Discussion about this post

User's avatar
Dr. Dereck Mush, MD, MBA's avatar

CMS already had a narrower tool it could have used. Since 13 July 2023 it has run a provisional period of enhanced oversight for newly enrolling hospices, with medical review including prepayment review, first in Arizona, California, Nevada and Texas, then in Georgia and Ohio from 30 December 2025. Turning to a national moratorium suggests CMS didn't think state-targeted review was working, and it would help if they published that evidence.

AkayJump's avatar

This feels like a strategy that can be backed up by the headway made regarding fraud. However, I can’t help but see the advantage this gives to billion dollar entities such as kinderhook. They can easily portray the buy outs that will likely ensue and already have, to be a benefit to HH and hospice as a whole. Without acknowledging the impact it will have on the quality of care and the choices that patients and communities will have when it comes to matter in end of life care

Ready for more?